News
:: Press Releases ::
1. May, 2010:
This report was recently issued by the Institute of Medicine. The report addresses use of biomarkers in claims for health foods and nutritional supplements:
http://www.iom.edu/Reports/2010/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Disease.aspx
2. February 16, 2010:
In this release, the Federal Trade Commission (FTC) sent warning letters to eleven companies that market omega-3 fatty acids supplements. The warning letters state that claims directed toward the brain and vision health of children may be deceptive. The FTC says the claims may be deceptive if there is no scientific evidence to back the claims. The companies have two weeks to respond.
http://www.ftc.gov/opa/2010/02/omega.shtm
3. February 14, 2010:
In this article that appeared in the widely read Week in Review section of the New York Times, Mark Bittman reviews the arguments for and against special taxes on drinks that contain added sugar. The taxes are being proposed by federal, state and local governments. The arguments generally center on the use and perceived dangers of drinks containing added sugar.
http://www.nytimes.com/2010/02/14/weekinreview/14bittman.html?scp=2&sq=Mark Bittman&st=cse
4. February 9, 2010:
"Will Congress Finally Reform Supplement Laws?" is a blog written by a physician that appeared on the Forbes website. It provides an opinion about the current Dietary Supplement Health and Education Act (DSHEA) and reasons for changing it.
http://blogs.forbes.com/sciencebiz/2010/02/will-congress-finally-reform-supplement-laws/?partner=artctrlinboxmain
5. February 3, 2010:
In response to the growing challenge of exercising oversight over clinical trial studies happening across multi-sites, the FDA has issued a draft guidance last month (January 2010) intended to assist IRBs in carrying out their continued review responsibility of these multi-site studies by proposing new recommendations of criteria, process and frequency of review. The guidance should also help clinical investigators and sponsors better understand their responsibilities in the continuing review process. This guidance is opened for comments and suggestions through the beginning of March 2010.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM197347.pdf
6. February 2, 2010:
An article in Forbes, entitled "Ten Misleading Drug Ads" reviews the FDA crackdown on companies that are not aggressively advertising serious side effects and adverse reactions to their pharmaceutical and cosmetic products.
http://www.forbes.com/2010/02/02/drug-advertising-lipitor-lifestyle-health-pharmaceuticals-safety.html
7. February 2, 2010:
In the Tuesday Science Section of The New York Times, there was a report on vitamin D supplements. Although vitamin D has been known for close to a century and sales of vitamin D supplements were $235 million in 2008, (up from $40 million in 2000), little is known about the optimal dosage of this critical molecule. In fact, many experts believe that the current recommendations of 400 I.U per day of vitamin D is much to low. Therefore, a five year randomized clinical trial using 1000 I.U. of vitamin D and 20,000 subjects is just getting underway at Brigham and Women's Hospital in Boston. The trial will also include omega-3 fish oil supplements.
http://well.blogs.nytimes.com/2010/02/01/the-miracle-of-vitamin-d-sound-science-or-hype/?scp=2&sq=tara%20parker-pope&st=cse
8. February 1, 2010:
The New York Times reported that the FDA sent a warning letter to a prominent dermatologist for making a public endorsement of a cosmetic product that has not been approved. Part of the reason for the warning letter is that the dermatologist was an investigator involved in the development of the product.
http://www.nytimes.com/2010/02/01/business/01wrinkle.html?ref=todayspaper
9. January 25, 2010:
Glaxo purchased a biotech company that was developing anti-aging drugs based on the red wine-ingredient resveratrol. However, recent studies performed by Pfizer suggest that the drugs won't work.
Below is the link to the news report in Forbes: http://www.forbes.com/2010/01/25/longevity-resveratrol-glaxosmithkline-healthcare-business-pfizer-amgen.html?partner=email
We also include the link to the research report that appeared in the Journal of Biological Chemistry: http://www.jbc.org/cgi/doi/10.1074/jbc.M109.088682
10. January 3, 2010:
Nicholas D. Kristoff, an Op Ed writer for the New York Times wrote an opinion piece on the deficiency of micronutrients in the diets of many people in the developing world. Mr. Kristoff discusses the importance of folic acid, iron, iodine and zinc in human health, particularly that of children. To see the full opinion piece, go to:
http://www.nytimes.com/2010/01/03/opinion/03kristof.html
- NMR Rapid Focus Study™ Press Release - August 4, 2010
- NMR Safety Monograph Press Release - March 24, 2010
-
::: 2010 :::
- August 2010 News: NMR's Rapid Focus StudyTM/Food Additives/Rain Forest Compounds
- July 2010 News: NMR Introduces the Rapid Focus Study / Glucosamine & Osteoarthritis
- June 2010 News: IFT 2010 Specials / DSHEA Act / FTC New Powers Blog
- May 2010 News: Technical Writing & Clinical Trials for Foods/Ingredients, Nuts & Heart Health, Probiotics
- April 2010 News: Free Speech About Science Act / Blog on Structure-Function Claim Guidance for Foods / Benefits of Cranberries & Tea Tree Oil
- March 2010 News: IHS & NPEW Recap/NMR Launches New Safety Monograph/Nutrition & Vision Month
- February 2010 News: Evidence & FTC, Brand Loyalty / FDA & IRBs / Chocolate & Omega-3s for Heart Health
- January 2010 News: Scientifically Reasoning the New FDA Guidance, Atopic Dermatitis, NMR at IHS
- November/December 2009 News: 2010 Industry Forecast on Dietary Supplements, Highlighting Evidence & Health Claims, NMR Specials Extended
- October 2009 News: Natural Products Expo East '09, FTC & SupplySide West '09 Specials
- September 2009 News: NMR Publishes Scientific Article in Nutraceuticals World
- August 2009 News: CRO Market, Maitake Update & Upcoming NMR Events
- July 2009 News: NMR Brings Evidence to Natural Marketplace '09
- June 2009 News: Building Awareness with Evidence
- May 2009 News: Tailoring Clinical Research to Fit Your Needs
- NMR News - Volume 2, Issue 1, March 2009
- NMR News - Volume 1, Issue 1, December 2008
::: 2009 :::
1. May, 2010:
This report was recently issued by the Institute of Medicine. The report addresses use of biomarkers in claims for health foods and nutritional supplements:
http://www.iom.edu/Reports/2010/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Disease.aspx
2. February 16, 2010:
In this release, the Federal Trade Commission (FTC) sent warning letters to eleven companies that market omega-3 fatty acids supplements. The warning letters state that claims directed toward the brain and vision health of children may be deceptive. The FTC says the claims may be deceptive if there is no scientific evidence to back the claims. The companies have two weeks to respond.
http://www.ftc.gov/opa/2010/02/omega.shtm
3. February 14, 2010:
In this article that appeared in the widely read Week in Review section of the New York Times, Mark Bittman reviews the arguments for and against special taxes on drinks that contain added sugar. The taxes are being proposed by federal, state and local governments. The arguments generally center on the use and perceived dangers of drinks containing added sugar.
http://www.nytimes.com/2010/02/14/weekinreview/14bittman.html?scp=2&sq=Mark Bittman&st=cse
4. February 9, 2010:
"Will Congress Finally Reform Supplement Laws?" is a blog written by a physician that appeared on the Forbes website. It provides an opinion about the current Dietary Supplement Health and Education Act (DSHEA) and reasons for changing it.
http://blogs.forbes.com/sciencebiz/2010/02/will-congress-finally-reform-supplement-laws/?partner=artctrlinboxmain
5. February 3, 2010:
In response to the growing challenge of exercising oversight over clinical trial studies happening across multi-sites, the FDA has issued a draft guidance last month (January 2010) intended to assist IRBs in carrying out their continued review responsibility of these multi-site studies by proposing new recommendations of criteria, process and frequency of review. The guidance should also help clinical investigators and sponsors better understand their responsibilities in the continuing review process. This guidance is opened for comments and suggestions through the beginning of March 2010.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM197347.pdf
6. February 2, 2010:
An article in Forbes, entitled "Ten Misleading Drug Ads" reviews the FDA crackdown on companies that are not aggressively advertising serious side effects and adverse reactions to their pharmaceutical and cosmetic products.
http://www.forbes.com/2010/02/02/drug-advertising-lipitor-lifestyle-health-pharmaceuticals-safety.html
7. February 2, 2010:
In the Tuesday Science Section of The New York Times, there was a report on vitamin D supplements. Although vitamin D has been known for close to a century and sales of vitamin D supplements were $235 million in 2008, (up from $40 million in 2000), little is known about the optimal dosage of this critical molecule. In fact, many experts believe that the current recommendations of 400 I.U per day of vitamin D is much to low. Therefore, a five year randomized clinical trial using 1000 I.U. of vitamin D and 20,000 subjects is just getting underway at Brigham and Women's Hospital in Boston. The trial will also include omega-3 fish oil supplements.
http://well.blogs.nytimes.com/2010/02/01/the-miracle-of-vitamin-d-sound-science-or-hype/?scp=2&sq=tara%20parker-pope&st=cse
8. February 1, 2010:
The New York Times reported that the FDA sent a warning letter to a prominent dermatologist for making a public endorsement of a cosmetic product that has not been approved. Part of the reason for the warning letter is that the dermatologist was an investigator involved in the development of the product.
http://www.nytimes.com/2010/02/01/business/01wrinkle.html?ref=todayspaper
9. January 25, 2010:
Glaxo purchased a biotech company that was developing anti-aging drugs based on the red wine-ingredient resveratrol. However, recent studies performed by Pfizer suggest that the drugs won't work.
Below is the link to the news report in Forbes: http://www.forbes.com/2010/01/25/longevity-resveratrol-glaxosmithkline-healthcare-business-pfizer-amgen.html?partner=email
We also include the link to the research report that appeared in the Journal of Biological Chemistry: http://www.jbc.org/cgi/doi/10.1074/jbc.M109.088682
10. January 3, 2010:
Nicholas D. Kristoff, an Op Ed writer for the New York Times wrote an opinion piece on the deficiency of micronutrients in the diets of many people in the developing world. Mr. Kristoff discusses the importance of folic acid, iron, iodine and zinc in human health, particularly that of children. To see the full opinion piece, go to:
http://www.nytimes.com/2010/01/03/opinion/03kristof.html
© 2010 Nutraceutical Medical Research. All rights reserved.
